Changes in circulating microRNA levels associated with prostate cancer - PubMed (original) (raw)

Changes in circulating microRNA levels associated with prostate cancer

R J Bryant et al. Br J Cancer. 2012.

Abstract

Background: The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer.

Methods: Real-time polymerase chain reaction analysis of 742 miRs was performed using plasma-derived circulating microvesicles of 78 prostate cancer patients and 28 normal control individuals to identify differentially quantified miRs.

Results: A total of 12 miRs were differentially quantified in prostate cancer patients compared with controls, including 9 in patients without metastases. In all, 11 miRs were present in significantly greater amounts in prostate cancer patients with metastases compared with those without metastases. The association of miR-141 and miR-375 with metastatic prostate cancer was confirmed using serum-derived exosomes and microvesicles in a separate cohort of patients with recurrent or non-recurrent disease following radical prostatectomy. An analysis of five selected miRs in urine samples found that miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls.

Conclusion: These observations suggest that changes in miR concentration in prostate cancer patients may be identified by analysing various body fluids. Moreover, circulating miRs may be used to diagnose and stage prostate cancer.

PubMed Disclaimer

Conflict of interest statement

TP and BR are employed by Caris Life Sciences; RV has been recipient of a commercial research grant from Caris Life Sciences.

Figures

Figure 1

Figure 1

Overview of miR analysis of plasma, serum and urine samples.

Figure 2

Figure 2

Taqman qRT–PCR analysis using an independent University of Washington serum cohort of exosome fractions verified the quantification changes of miR-375 (A) and miR-141 (B) (_P_=0.0001 Mann–Whitney U test).

Figure 3

Figure 3

MicroRNAs-107 and 574-3p in urinary prostate cells are associated with the presence of cancer. (A) The quantity (shown as ΔCt values with respect to reference snoRNAs) is higher in prostate cancer cases, when compared with controls. (B) This quantification can be used to identify the presence of prostate cancer from urine samples (AUC ROC shown in brackets).

Similar articles

Cited by

References

    1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233 - PMC - PubMed
    1. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608–616 - PubMed
    1. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671–681 - PubMed
    1. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69: 8472–8481 - PMC - PubMed
    1. Ciatto S, Zappa M, Bonardi R, Gervasi G (2000) Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. Eur J Cancer 36: 1347–1350 - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources